Hims & Hers Health, Inc. Q3 2026 Earnings Recap

Hims & Hers fell 16.6% after earnings, as investors appear to have focused on management’s planned trade-off of near-term subscriber growth for longer-term positioning. The company said it pulled back on weight-loss marketing and will redeploy investment ahead of the new year, while emphasizing future opportunities rather than near-term growth.

Key Takeaways

• Revenue growth accelerated to nearly 50%, according to management.
• Nearly 3 million people across four continents use the platform.
• Management said it intentionally reduced weight-loss marketing as it prepared new offerings and international investment, acknowledging this trades near-term subscriber growth for a stronger future position.
• The company plans to put its next wave of marketing investment to work ahead of the new year, when management expects seasonal interest in weight loss to peak.
• Hims & Hers said it is launching testosterone replacement therapy this quarter and Peptides+ later this month.